Fresenius Medical Care Corporation (NYSE:FMS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday, October 9th. The brokerage currently has a $53.00 target price on the stock. Zacks Investment Research‘s target price suggests a potential upside of 10.19% from the company’s current price.
According to Zacks, “Fresenius Medical Care has had a disappointing run on the bourse on a year-to-date basis. The company ended the second quarter on a mixed note wherein adjusted earnings missed the Zacks Consensus Estimate, while revenues beat the same. Fresenius Medical Care reiterated its full-year guidance. We believe this is in tune with the company’s long-term objective or the ‘Growth Strategy 2020’, wherein it aims to drive revenues to $28 billion by 2020, corresponding to an average annual growth rate of 10%. A wide range of dialysis products, initiatives to attain market traction, solid international foothold, strategic acquisitions and divestments are major catalysts. Fresenius Medical Care has signed an agreement to acquire NxStage Medical for $2 billion. However, a tough regulatory environment, difficulties in boosting the profit margin in foreign legal paradigms and competition in the niche markets are major headwinds.”
FMS has been the topic of a number of other reports. Nord/LB reaffirmed a “buy” rating on shares of Fresenius Medical Care Corporation in a report on Wednesday, June 28th. Royal Bank Of Canada reissued a “neutral” rating on shares of Fresenius Medical Care Corporation in a report on Tuesday, August 1st. BidaskClub cut shares of Fresenius Medical Care Corporation from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. DZ Bank AG reissued a “buy” rating on shares of Fresenius Medical Care Corporation in a report on Monday, August 7th. Finally, UBS AG reissued a “sell” rating on shares of Fresenius Medical Care Corporation in a report on Tuesday, July 4th. One research analyst has rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the stock. Fresenius Medical Care Corporation presently has an average rating of “Hold” and an average price target of $48.50.
Fresenius Medical Care Corporation (FMS) traded up 0.87% on Monday, hitting $48.52. The stock had a trading volume of 51,771 shares. Fresenius Medical Care Corporation has a 12-month low of $38.05 and a 12-month high of $50.22. The company’s 50 day moving average price is $48.26 and its 200-day moving average price is $46.87. The company has a market cap of $29.78 billion, a price-to-earnings ratio of 20.82 and a beta of 0.48.
Fresenius Medical Care Corporation (NYSE:FMS) last posted its quarterly earnings data on Tuesday, August 1st. The company reported $0.48 EPS for the quarter, missing the Zacks’ consensus estimate of $0.53 by ($0.05). Fresenius Medical Care Corporation had a return on equity of 11.57% and a net margin of 7.06%. The business had revenue of $4.47 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same quarter in the prior year, the company earned $0.96 earnings per share. The company’s quarterly revenue was up 11.1% on a year-over-year basis. Equities research analysts anticipate that Fresenius Medical Care Corporation will post $2.35 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/fresenius-medical-care-corporation-fms-upgraded-to-hold-by-zacks-investment-research/1702305.html.
A number of institutional investors have recently modified their holdings of the business. Harding Loevner LP lifted its holdings in shares of Fresenius Medical Care Corporation by 6.2% during the second quarter. Harding Loevner LP now owns 3,748,173 shares of the company’s stock worth $181,149,000 after purchasing an additional 219,213 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Fresenius Medical Care Corporation during the first quarter worth $7,141,000. Bank of America Corp DE lifted its holdings in shares of Fresenius Medical Care Corporation by 12.1% during the first quarter. Bank of America Corp DE now owns 1,493,411 shares of the company’s stock worth $62,917,000 after purchasing an additional 161,262 shares during the period. Cambiar Investors LLC lifted its holdings in shares of Fresenius Medical Care Corporation by 3.2% during the second quarter. Cambiar Investors LLC now owns 2,596,480 shares of the company’s stock worth $125,488,000 after purchasing an additional 80,064 shares during the period. Finally, Oppenheimer Asset Management Inc. acquired a new position in shares of Fresenius Medical Care Corporation during the first quarter worth $3,219,000. Hedge funds and other institutional investors own 2.61% of the company’s stock.
Fresenius Medical Care Corporation Company Profile
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with our FREE daily email newsletter.